Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Study results from United States Army Medical Research Institute of Infectious Disease, Department of Molecular Virology in the area of vaccines published
July 23rd, 2008
New research, 'Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine,' is the subject of a report. According to recent research published in the journal Virology, "We previously developed a gene-based vaccine, termed 4pox, which targets four orthopoxvirus proteins (A33, L1, B5, and A27). Because any subunit orthopoxvirus vaccine must protect against multiple species of orthopoxviruses, we are interested in understanding the cross-protective potential of our 4pox vaccine target immunogens." "In our current studies, we focused on the A33 immunogen. We found one monoclonal antibody against A33, MAb-1G10, which...
Source: Vaccine Weekly (2008-07-23)
|
